<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medinfo</journal-id><journal-title-group><journal-title xml:lang="ru">Актуальные проблемы теоретической и клинической медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Actual Problems of Theoretical and Clinical Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2790-1289</issn><issn pub-type="epub">2790-1297</issn><publisher><publisher-name>Казахстанско-Российский медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.64854/2790-1289-2026-53-3-07</article-id><article-id custom-type="elpub" pub-id-type="custom">medinfo-1094</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ОЦЕНКА РИСКОВ КАЧЕСТВА ТЕХНОЛОГИИ ТАБЛЕТОК ДЛЯ РАССАСЫ-ВАНИЯ С ЭКСТРАКТОМ AJANIA FRUTICULOSA (LEDEB.) POLJAK В РАМ-КАХ КОНЦЕПЦИИ QUALITY BY DESIGN</article-title><trans-title-group xml:lang="en"><trans-title>QUALITY RISK ASSESSMENT OF A DIRECT COMPRESSION TECHNOLOGY FOR LOZENGES CONTAINING AJANIA FRUTICULOSA (LEDEB.) POLJAK EX-TRACT WITHIN THE QUALITY BY DESIGN FRAMEWORK</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5239-9429</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джакиянов</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Jakiyanov</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ассистент профессора кафедры биотехнологии и общей химической технологии КазНМУ им. Асфендиярова</p></bio><email xlink:type="simple">jakiyanov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1400-1971</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сакипова</surname><given-names>З. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sakipova</surname><given-names>Z. B.</given-names></name></name-alternatives><email xlink:type="simple">sakipova.z@kaznmu.kz</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0801-0508</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алламбергенова</surname><given-names>З. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Allambergenova</surname><given-names>Z. B.</given-names></name></name-alternatives><email xlink:type="simple">allambergenova.z@kaznmu.kz</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5288-6742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кадырбай</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kadyrbay</surname><given-names>A.</given-names></name></name-alternatives><email xlink:type="simple">akadyrbai@vivapharm.kz</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9631-0112</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кульманбетов</surname><given-names>Р. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulmanbetov</surname><given-names>R. I.</given-names></name></name-alternatives><email xlink:type="simple">kulmanbetov.r@kaznmu.kz</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1268-9867</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ибадуллаева</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ibadullayeva</surname><given-names>G. S.</given-names></name></name-alternatives><email xlink:type="simple">arujan-d@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-6902-6262</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сулейменов</surname><given-names>М. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Suleimenov</surname><given-names>M. K.</given-names></name></name-alternatives><email xlink:type="simple">suleimenov.m@kaznmu.kz</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НАО «Казахский национальный медицинский университет имени С. Д. Асфендияро-ва», Казахстан, Алматы</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>NJSC «S. D. Asfendiyarov Kazakh National Medical University», Kazakhstan, Almaty</institution><country>Kazakhstan</country></aff></aff-alternatives><aff xml:lang="ru" id="aff-2"><institution>ТОО «Viva Pharm», Казахстан, Алматы</institution><country>Kazakhstan</country></aff><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>НАО «Казахский национальный медицинский университет имени С. Д. Асфендиярова», Казахстан, Алматы</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>NJSC «S. D. Asfendiyarov Kazakh National Medical University», Kazakhstan, Almaty</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>05</day><month>10</month><year>2026</year></pub-date><volume>0</volume><issue>3</issue><elocation-id>1094</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Джакиянов А., Сакипова З., Алламбергенова З., Кадырбай А., Кульманбетов Р., Ибадуллаева Г., Сулейменов М., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Джакиянов А., Сакипова З., Алламбергенова З., Кадырбай А., Кульманбетов Р., Ибадуллаева Г., Сулейменов М.</copyright-holder><copyright-holder xml:lang="en">Jakiyanov A., Sakipova Z., Allambergenova Z., Kadyrbay A., Kulmanbetov R., Ibadullayeva G., Suleimenov M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://kazrosmedjournal.krmu.edu.kz/jour/article/view/1094">https://kazrosmedjournal.krmu.edu.kz/jour/article/view/1094</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Прямое прессование позволяет получать таблетки для рассасывания без стадий влажного гранулирования и сушки. Однако вариабельность свойств растительных экстрактов может влиять на воспроизводимость критических показателей качества. Управление рисками в рамках концепции Quality by Design позволяет систематизировать источники вариабельности и обосновать стратегию контроля.</p></sec><sec><title>Цель</title><p>Цель. Идентифицировать и оценить риски качества при разработке технологии прямого прессования таблеток для рассасывания с сухим экстрактом Ajania fruticulosa (Ledeb.) Poljak.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Потенциальные источники вариабельности систематизированы с помощью причинно-следственной диаграммы Исикавы. Ранжирование рисков выполнено методом анализа видов и последствий отказов (FMEA). Тяжесть последствий, вероятность возникновения и обнаруживаемость оценивали по пятибалльным шкалам с расчётом приоритетного числа риска (RPN). Остаточные риски прогнозировали путём повторной экспертной оценки вероятности возникновения и обнаруживаемости с учётом предложенных мер; тяжесть последствий оставляли неизменной.</p></sec><sec><title>Результаты</title><p>Результаты. Выявлены 36 потенциальных факторов вариабельности, из которых для FMEA отобраны семь приоритетных режимов отказа. Исходные значения RPN составили 18–48. Наибольший риск связан с сегрегацией порошковой смеси при подаче в зону питателя. В сценарии применения предложенных мер прогнозируемые остаточные значения RPN составили 6–24. Шесть из семи режимов отказа отнесены к области низкого риска, включая пять, первоначально классифицированных как средний риск. Сегрегация смеси сохранила средний уровень риска и требует дальнейшего контроля.</p></sec><sec><title>Выводы</title><p>Выводы. Предложенная стратегия контроля служит основой для дальнейшей разработки, трансфера и масштабирования технологии. Снижение риска основано на экспертном прогнозе и требует экспериментального подтверждения посредством измерения соответствующих критических показателей качества.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Direct compression enables lozenge manufacturing without wet granulation and drying. However, variability in the properties of herbal extracts may affect the reproducibility of critical quality attributes. Quality risk management within the Quality by Design framework supports systematic identification of variability sources and justification of a control strategy.</p></sec><sec><title>Objective</title><p>Objective. To identify and assess quality risks during the development of a direct compression technology for lozenges containing dry Ajania fruticulosa (Ledeb.) Poljak extract.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Potential sources of variability were structured using an Ishikawa cause-and-effect diagram. Risks were ranked using Failure Mode and Effects Analysis. Severity, occurrence, and detectability were assessed using five-point scales, and Risk Priority Numbers (RPNs) were calculated. Residual risks were predicted by expert reassessment of occurrence and detectability under the proposed mitigation scenario, while severity scores remained unchanged.</p></sec><sec><title>Results</title><p>Results. Thirty-six potential variability factors were identified, and seven priority failure modes were selected for Failure Mode and Effects Analysis. Initial RPNs ranged from 18 to 48. Powder blend segregation during feeding into the hopper zone had the highest initial RPN. Under the proposed mitigation scenario, predicted residual RPNs ranged from 6 to 24. Six of the seven failure modes were classified as low risk, including five initially classified as medium risk. Powder blend segregation remained a medium risk requiring continued monitoring.</p></sec><sec><title>Conclusions</title><p>Conclusions. The proposed control strategy provides a basis for further process development, technology transfer, and scale-up. Risk reduction represents an expert prediction and requires experimental confirmation through measurement of the corresponding critical quality attributes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>таблетки</kwd><kwd>растительные экстракты</kwd><kwd>управление рисками</kwd><kwd>контроль качества</kwd><kwd>Ajania fruticulosa</kwd><kwd>Quality by Design</kwd><kwd>диаграмма Исикавы</kwd><kwd>анализ видов и последствий отказов.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Tablets</kwd><kwd>Plant Extracts</kwd><kwd>Risk Management</kwd><kwd>Quality Control</kwd><kwd>Ajania fruticulosa</kwd><kwd>Quality by De-sign</kwd><kwd>Ishikawa diagram</kwd><kwd>Failure Mode and Effects Analysis.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. Retrieved April 9, 2026, from https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf</mixed-citation><mixed-citation xml:lang="en">International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: International Council for Harmonisation, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">International Council for Harmonisation. (2023). ICH Q9(R1): Quality risk management. Retrieved April 9, 2026, from https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-r1-quality-risk-management-step-5-revision-2_en.pdf</mixed-citation><mixed-citation xml:lang="en">International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: International Council for Harmonisation, 2023.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">International Council for Harmonisation. (2008). ICH Q10: Pharmaceutical quality system. Retrieved April 9, 2026, from https://database.ich.org/sites/default/files/Q10%20Guideline.pdf</mixed-citation><mixed-citation xml:lang="en">International Council for Harmonisation. ICH Q10: Pharmaceutical Quality System. Geneva: International Council for Harmonisation, 2008.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yang, S., Hu, X., Zhu, J., Zheng, B., Bi, W., Wang, X., Wu, J., Mi, Z., &amp; Wu, Y. (2025). Aspects and implementation of pharmaceutical quality by design from conceptual frameworks to industrial applications. Pharmaceutics, 17(5), 623. DOI: https://doi.org/10.3390/pharmaceutics17050623</mixed-citation><mixed-citation xml:lang="en">Yang S., Hu X., Zhu J., Zheng B., Bi W., Wang X., Wu J., Mi Z., Wu Y. Aspects and implementation of pharmaceutical Quality by Design from conceptual frameworks to industrial applications. Pharmaceutics, 2025, vol. 17, no. 5, article 623. DOI: 10.3390/pharmaceutics17050623.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gurski, C. S., Luna Lazo, R. E., Gelinski, M. A., Alves, L. A., Sovinski, M. S., Sari, M. H. M., Borba, H. H. L., Tonin, F. S., Pontarolo, R., &amp; Ferreira, L. M. (2025). Quality by design applied to pediatric-friendly formulations: A scoping review-based manufacturing process map-ping for solid dosage forms. Journal of Drug Delivery Science and Technology, 108, 106915. DOI: https://doi.org/10.1016/j.jddst.2025.106915</mixed-citation><mixed-citation xml:lang="en">Gurski C.S., Luna Lazo R.E., Gelinski M.A., Alves L.A., Sovinski M.S., Sari M.H.M., Borba H.H.L., Tonin F.S., Pontarolo R., Ferreira L.M. Quality by Design applied to pediatric-friendly formulations: a scoping review-based manufacturing process mapping for solid dosage forms. Journal of Drug Delivery Science and Technology, 2025, vol. 108, article 106915. DOI: 10.1016/j.jddst.2025.106915.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Simão, J., Chaudhary, S. A., &amp; Ribeiro, A. J. (2023). Implementation of quality by design for development of bilayer tablets. European Journal of Pharmaceutical Sciences, 184, 106412. DOI: https://doi.org/10.1016/j.ejps.2023.106412</mixed-citation><mixed-citation xml:lang="en">Simão J., Chaudhary S.A., Ribeiro A.J. Implementation of Quality by Design for development of bilayer tablets. European Journal of Pharmaceutical Sciences, 2023, vol. 184, article 106412. DOI: 10.1016/j.ejps.2023.106412.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Casian, T., Iurian, S., Bogdan, C., Rus, L., Moldovan, M., &amp; Tomuta, I. (2017). Quality by design for pediatric oral lyophilisates development: Risk assessment followed by screening and optimization. Drug Development and Industrial Pharmacy, 43(12), 1932-1944. DOI: https://doi.org/10.1080/03639045.2017.1350702</mixed-citation><mixed-citation xml:lang="en">Casian T., Iurian S., Bogdan C., Rus L., Moldovan M., Tomuta I. Quality by Design for pediatric oral lyophilisates development: risk assessment followed by screening and optimization. Drug Development and Industrial Pharmacy, 2017, vol. 43, no. 12, pp. 1932–1944. DOI: 10.1080/03639045.2017.1350702.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kaljević, O., Djuriš, J., Djurić, Z., &amp; Ibrić, S. (2016). Application of failure mode and effects analysis in quality by design approach for formulation of carvedilol compression coated tablets. Journal of Drug Delivery Science and Technology, 32, 56-63. DOI: https://doi.org/10.1016/j.jddst.2016.02.004</mixed-citation><mixed-citation xml:lang="en">Kaljević O., Djuriš J., Djurić Z., Ibrić S. Application of failure mode and effects analysis in Quality by Design approach for formulation of carvedilol compression coated tablets. Journal of Drug Delivery Science and Technology, 2016, vol. 32, pp. 56–63. DOI: 10.1016/j.jddst.2016.02.004.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nait Bachir, Y., Said, R. M., Terki, N. Z., Antar, R., Slamani, M., Gharbi, D., &amp; Foligni, R. (2025). Biopharmaceutical and pharmacotechnical characterization of plant powder tablets ob-tained by direct compression process: The case of Atriplex halimus. Applied Sciences, 15(15), Article 8623. DOI: https://doi.org/10.3390/app15158623</mixed-citation><mixed-citation xml:lang="en">Naman S., Madhavi N., Singh B., Madan J., Baldi A. Implementing risk-based Quality by Design for development and optimization of flavored oral disintegrating mini tablets. Journal of Drug Delivery Science and Technology, 2021, vol. 66, article 102799. DOI: 10.1016/j.jddst.2021.102799.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pham, E. C., Vo Van, L., Nguyen, C. V., Nguyen Duong, N. T., &amp; Le Thi, T. V. (2023). Formulation development, optimization, in vivo antidiabetic effect and acute toxicity of directly compressible herbal tablets containing Merremia tridentata (L.) extract. Journal of Drug Deliv-ery Science and Technology, 84, Article 104445. DOI: https://doi.org/10.1016/j.jddst.2023.104445</mixed-citation><mixed-citation xml:lang="en">Tafere C., Yilma Z., Abrha S., Yehualaw A. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression. PLOS ONE, 2021, vol. 16, no. 3, article e0246648. DOI: 10.1371/journal.pone.0246648.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tafere, C., Yilma, Z., Abrha, S., &amp; Yehualaw, A. (2021). Formulation, in vitro character-ization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression. PLOS ONE, 16(3), Article e0246648. DOI: https://doi.org/10.1371/journal.pone.0246648</mixed-citation><mixed-citation xml:lang="en">Nait Bachir Y., Said R.M., Terki N.Z., Antar R., Slamani M., Gharbi D., Foligni R. Biopharmaceutical and pharmacotechnical characterization of plant powder tablets obtained by direct compression process: the case of Atriplex halimus. Applied Sciences, 2025, vol. 15, no. 15, article 8623. DOI: 10.3390/app15158623.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Naman, S., Madhavi, N., Singh, B., Madan, J., &amp; Baldi, A. (2021). Implementing risk-based quality by design for development and optimization of flavored oral disintegrating mini tablets. Journal of Drug Delivery Science and Technology, 66, 102799. DOI: https://doi.org/10.1016/j.jddst.2021.102799</mixed-citation><mixed-citation xml:lang="en">Pham E.C., Vo Van L., Nguyen C.V., Nguyen Duong N.T., Le Thi T.V. Formulation development, optimization, in vivo antidiabetic effect and acute toxicity of directly compressible herbal tablets containing Merremia tridentata (L.) extract. Journal of Drug Delivery Science and Technology, 2023, vol. 84, article 104445. DOI: 10.1016/j.jddst.2023.104445.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dzhakiyanov, A. M., Ridvanov, Ch. I., Isaev, Zh. N., Zhumashova, G. T., Bekezhano-va, T. S., Kulmanbetov, R. I., Talgaeva, E. V., Turuspaeva, Zh. Zh., Sakipova, Z. B., &amp; Sulei-menov, M. K. (2026). Razrabotka sostava i tekhnologii tabletok dlya rassasyvaniya s ekstraktom Ajania fruticulosa (Ledeb.) Poljak s primeneniem kontseptsii quality by design. De-velopment and registration of medicines, 15(1), 85-95. DOI: https://doi.org/10.33380/2305-2066-2026-15-1-2233</mixed-citation><mixed-citation xml:lang="en">Jakiyanov A.M., Ridvanov Ch.I., Isaev Zh.N., Zhumashova G.T., Bekezhanova T.S., Kulmanbetov R.I., Talgaeva E.V., Turuspaeva Zh.Zh., Sakipova Z.B., Suleimenov M.K. Razrabotka sostava i tekhnologii tabletok dlya rassasyvaniya s ekstraktom Ajania fruticulosa (Ledeb.) Poljak s primeneniem kontseptsii Quality by Design [Development of the composition and technology of lozenges with Ajania fruticulosa (Ledeb.) Poljak extract using the Quality by Design concept]. Razrabotka i registratsiya lekarstvennykh sredstv, 2026, vol. 15, no. 1, pp. 85–95. DOI: 10.33380/2305-2066-2026-15-1-2233. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liang, J., Lu, P., Ning, A., Yang, Y., Shao, Y., &amp; Xu, J. (2020). Chemical constituents from the aerial parts of Ajania fruticulosa. Biochemical Systematics and Ecology, 92, 104124. DOI: https://doi.org/10.1016/j.bse.2020.104124</mixed-citation><mixed-citation xml:lang="en">Liang J., Lu P., Ning A., Yang Y., Shao Y., Xu J. Chemical constituents from the aerial parts of Ajania fruticulosa. Biochemical Systematics and Ecology, 2020, vol. 92, article 104124. DOI: 10.1016/j.bse.2020.104124.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Min, X., Chen, J., Mu, W., Huang, J., Huang, G., &amp; Cao, J. (2025). A new dimeric ses-quiterpenoid from Ajania fruticulosa. Phytochemistry Letters, 66, 60-65. https://doi.org/10.1016/j.phytol.2025.02.001</mixed-citation><mixed-citation xml:lang="en">Min X., Chen J., Mu W., Huang J., Huang G., Cao J. A new dimeric sesquiterpenoid from Ajania fruticulosa. Phytochemistry Letters, 2025, vol. 66, pp. 60–65. DOI: 10.1016/j.phytol.2025.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dzhakiyanov, A. M., Sakipova, Z. B., Ibragimova, L. N., Ibraeva, M. B., Kaldybaeva, A. M., &amp; Ensebaeva, G. B. (2025). Farmatsevticheskaya kompozitsiya iz rastitel’noi substantsii s antibakterial’nym i protivogribkovym deistviem i sposob ee polucheniya (Kazakhstan Utility Model Patent No. 11229). Kazakhstan National Institute of Intellectual Property. Retrieved April 9, 2026, from https://gosreestr.kazpatent.kz/Utilitymodel/Details?docNumber=429851</mixed-citation><mixed-citation xml:lang="en">Jakiyanov A.M., Sakipova Z.B., Ibragimova L.N., Ibraeva M.B., Kaldybaeva A.M., Ensebaeva G.B. Farmatsevticheskaya kompozitsiya iz rastitel'noi substantsii s antibakterial'nym i protivogribkovym deistviem i sposob ee polucheniya [Pharmaceutical composition from a plant substance with antibacterial and antifungal activity and a method for its preparation]. Republic of Kazakhstan utility-model patent No. 11229, Bulletin No. 40, 3 October 2025. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Liu, H.-C., Chen, X.-Q., Duan, C.-Y., &amp; Wang, Y.-M. (2019). Failure mode and effect analysis using multi-criteria decision making methods: A systematic literature review. Computers &amp; Industrial Engineering, 135, 881-897. DOI: https://doi.org/10.1016/j.cie.2019.06.055</mixed-citation><mixed-citation xml:lang="en">Liu, H.-C., Chen, X.-Q., Duan, C.-Y., &amp; Wang, Y.-M. (2019). Failure mode and effect analysis using multi-criteria decision making methods: A systematic literature review. Computers &amp; Industrial Engineering, 135, 881-897. DOI: https://doi.org/10.1016/j.cie.2019.06.055</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ccopa Ibarra, L. A., Fontenele Urano de Carvalho, E., &amp; Durazzo, M. (2024). Over-coming FMEA shortcomings: Proposal of an adapted risk analysis matrix. Engineering Failure Analysis, 166, 108796. DOI: https://doi.org/10.1016/j.engfailanal.2024.108796</mixed-citation><mixed-citation xml:lang="en">Ccopa Ibarra, L. A., Fontenele Urano de Carvalho, E., &amp; Durazzo, M. (2024). Over-coming FMEA shortcomings: Proposal of an adapted risk analysis matrix. Engineering Failure Analysis, 166, 108796. DOI: https://doi.org/10.1016/j.engfailanal.2024.108796</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
